PROJECT VOLGA

Location:

Russia

Project number:

35135

Business sector:

Manufacturing and Services

Notice type:

Private

Environmental category:

B

Target board date:

21 Sep 2004

Status:

Completed

PSD disclosed:

03 Aug 2005

Project Description

The proposed project is an extension of the first €15 million EBRD loan approved by the Bank in September 2004, and consists of an additional €10 million long term Loan to NPO Petrovax Pharm, a Russian niche pharmaceutical company based in Moscow. The loan will be used to finance construction of a greed field facility near Moscow to manufacture a new generation influenza vaccine for the Russian and CIS market.
The Project is a result of collaboration efforts of Petrovax and a major international pharmaceutical player, Solvay.  It is unique as combines the achievements of Russian and Western scientific research and it promotes local production of a new drug in an important pharmacological area.

Transition Impact

The proposed project has strategic importance for the Russian pharmaceutical industry and is expected to have a significant transition impact as it will:
(i) finance construction of a GMP standard pharmaceutical facility to produce the new generation influenza vaccine which will combine latest technological and scientific developments;
(ii) support the Russian pharmaceutical industry which is lagging behind compared to Eastern and Western Europe and is dominated by old generation poor quality medicine;
(iii) serve as an example of efficient cooperation between a small local company and a reputable foreign strategic investor and promote competition in the generics dominated domestic pharma market prompting local producers to develop new technology by investing in R&D.

The Client

The loan will be provided to SPV set up by NPO Petrovax Pharm, specifically for the purpose of project implementation and 100% owned by NPO Petrovax Pharm.
Solvay, a leading European chemicals and pharmaceuticals group will provide project implementation and management support.

EBRD Finance

A long term €25,000,000 loan

Project Cost

€ 40,000,000

Environmental Impact

Project description
The proposed project consists of a loan to NPO Petrovax Pharm, a Russian niche pharmaceutical company based in Moscow. The loan will be used to finance construction of a green field facility near Moscow to manufacture a new generation vaccines, e.g. influenza vaccine, for the Russian and CIS market. The Project is a result of collaboration efforts of Petrovax and a major international pharmaceutical player, Solvay, which is a leading European chemicals and pharmaceuticals group. Solvay will provide project implementation and management support.
Environmental, health and safety issues
The Project has been categorised B/0. Environmental, health and safety risks associated with construction and operation of this pharmaceutical plant are not significant. The Bank’s environmental analysis has been based on the Environmental Impact Assessment (August 2004) prepared by an independent environmental consultant on behalf of the client. EBRD’s Initial Environmental Examination, carried out by ED staff member in May 2004, indicated that there are no environmental sensitivities associated with the project. The site was chosen among several alternatives on the basis of its good transport links and low ecological value. The proposed project site is adjacent to the existing motorway Moscow- Serpukhov and although the land plot it is formally classified as “agricultural”, there are no crops that have ever been grown on it. There are about twenty country houses located in the vicinity of the site (ca. 100 m away). However, this fact does not represent potential issue of concern as the residents have been informed about the future plans and have not expressed any objections to the project due to the fact that the required sanitary protection zone of 50 m will be observed.  The nearest local river (Pakhra) is 1 km away from the project site.  The Bank's environmental due diligence confirmed that the new plant will be built in accordance with applicable national environmental, health and safety requirements, with Good Manufacturing Practice (GMP) standards and generally in line with the World Bank Pollution Prevention Guidelines for Pharmaceuticals Manufacturing. No stand alone environmental action plan is required as the project design provides for minimisation of the environmental, health and safety impacts associated with construction and operation of the plant.  
This Environmental Review Summary is being released locally by the client  in accordance with EBRD's Environmental Policy and Procedures.
Air emissions
Key air emissions will include ethyl alcohol (from the antiseptic maintance of equipment surfaces); peroxide (from cleaning);  nitrogen and carbon oxides, benzopyrene (from gas-fired hobs and boiler); volatile organic components, benzene hydrocarbons, sulphur oxides, ash (from the car park and garage). All the emissions will be within the maximum permissible emissions levels calculated on the basis of the applicable national standards for the maximum permissible concentrations (MPC) of the corresponding pollutants in the atmospheric air.  
Effluent discharges
There will be no polluted process wastewaters as the project design envisaged closed loop water system (95% of water will be recirculated). The  waste waters from the maintenance operation can be classified as sanitary and will be discharged into the municipal sewer system. The stormwater will be sent via the  drainage system to on-site waste water treatment facilities and than discharged onto the relief/used in watering the site.
Solid and hazardous waste management
Key types of solid and hazardous waste from the production process and general operating practices will include mercury lamps, packaging waste, filters, rubber cuttings, polymeric waste (plastic containers), metal scrap, cloth, waste paper and solid municipal waste.  All these will be stored temporarily on-site in designated areas and than either handed over to subcontractors for further recycling and re-use, as appropriate, or transported to a municipal landfill in accordance with the local waste managements regulations.
Noise 
The noise levels resulting from the production facilities in the distance of 50-100 m from the boundary of the plant's sanitary protection zone  (in the area of the country houses cluster) will be 20dBa, which is well below the applicable World Bank Guidelines (55 and 45 dBA during the day and at night respectively for the residential areas).
Emergency response planning and preparedness
In the event of an accident or emergency the machinery in the plant shuts down automatically.  The plant will co-ordinate with the municipal fire service to ensure a timely and adequate response to any emergency situation.  Emergency response plan will be developed in a due course and will be reviewed by the Bank upon its submission.
Employee health and safety
Health and safety issues are, likewise, well recognised and managed by the client. Training will be provided when new employees start and repeated at regular intervals during the year.  Health and safety controllers will be in charge of monitoring compliance with health and safety requirements and there will be a variety of sanctions which can be applied for non-compliance with health and safety rules.
Environmental opportunities
There is likely to be a range of positive environmental opportunities associated with this project particularly those in relation to the proposed development of Good Manufacturing Practice (GMP) as well as the ISO 14001 and OHSAS18001 standards adhered to by Solvay, which will provide the implementation and management support for the project.
Monitoring and compliance
This will take form of annual environmental reports and periodic monitoring visits of the Bank’s ED staff as required.

Technical Cooperation

None.

Company Contact

NPO Petrovax Pharm
Arkadiy Nekrasov, General director
E-mail: info@petrovax-lab.com
Tel/fax: 095 117 8177
Web: http://www.polyoxidonium.ru
 

Business opportunities

For business opportunities or procurement, contact the client company.

For state-sector projects, visit EBRD Procurement: Tel: +44 20 7338 6794
Email: procurement@ebrd.com

General enquiries

EBRD project enquiries not related to procurement:
Tel: +44 20 7338 7168
Email: projectenquiries@ebrd.com

Public Information Policy (PIP)

The PIP sets out how the EBRD discloses information and consults with its stakeholders so as to promote better awareness and understanding of its strategies, policies and operations. Please visit the Public Information Policy page below to find out how to request a Public Sector Board Report.
Text of the PIP

Project Complaint Mechanism (PCM)

The Project Complaint Mechanism (PCM) is the EBRD's accountability mechanism. It provides an opportunity for an independent review of complaints from individuals and organisations concerning EBRD-financed projects which are alleged to have caused, or are likely to cause, environmental and/or social harm.

Please visit the Project Complaint Mechanism page to find information about how to submit a complaint. The PCM Officer (pcm@ebrd.com) is available to answer any questions you may have regarding the submission of a complaint and criteria for registration and eligibility, in accordance with the PCM Rules of Procedure.